EUS-Guided Fine Needle Biopsy Market Trends and Forecast
The future of the global EUS-guided fine needle biopsy market looks promising with opportunities in the hospitals and clinics markets. The global EUS-guided fine needle biopsy market is expected to grow with a CAGR of 5.5% from 2025 to 2031. The major drivers for this market are the rising accuracy and diagnostic capabilities and the growing adoption of minimally invasive procedures.
• Lucintel forecasts that, within the type category, enteral endoscopic ultrasound needles are expected to witness higher growth over the forecast period.
• Within the application category, the hospital is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the EUS-Guided Fine Needle Biopsy Market
The EUS-guided fine needle biopsy market is evolving with the introduction of new technologies and shifts in healthcare practices. Several emerging trends are influencing the way EUS-FNB procedures are performed and expanding their applications in clinical settings.
• Minimally Invasive Procedures: There is an increasing trend toward minimally invasive procedures in diagnostics, and EUS-FNB plays a key role in this shift. With fewer complications, shorter recovery times, and greater patient comfort, this trend has spurred the widespread adoption of EUS-FNB in hospitals and clinics. Patients prefer procedures that offer less pain and quicker recovery, which boosts the demand for EUS-FNB, particularly in gastrointestinal and pancreatic cancer diagnostics. The trend toward non-invasive procedures aligns with healthcare systems’ focus on improving patient care and reducing healthcare costs.
• Technological Integration with Imaging Systems: The integration of EUS-FNB with advanced imaging systems, such as real-time ultrasound and CT scans, is a prominent trend. This integration enables more accurate targeting and navigation, improving the precision of tissue sampling during the biopsy. The ability to visualize the tissue in real time ensures that biopsies are obtained from the correct location, reducing the risk of errors and increasing diagnostic accuracy. As imaging technologies improve, the demand for EUS-FNB devices with enhanced capabilities is expected to increase, reshaping how biopsies are performed in clinical settings.
• AI-Assisted Diagnostics: The incorporation of artificial intelligence (AI) into EUS-FNB is revolutionizing the biopsy process. AI-assisted diagnostics can help clinicians analyze ultrasound images and guide the needle placement with greater accuracy. This reduces human error and improves the quality of tissue samples collected during the procedure. As AI technologies become more advanced, their integration into EUS-FNB systems is expected to streamline the diagnostic process, reduce procedural time, and enhance the overall accuracy of cancer and other disease diagnoses.
• Improved Biopsy Needle Designs: Advancements in the design of biopsy needles used in EUS-FNB procedures are a critical trend. Manufacturers are focusing on creating needles that are not only more flexible and precise but also capable of obtaining larger tissue samples with less trauma to surrounding tissues. These innovations in needle design are improving diagnostic yields and reducing complications such as bleeding or infection. Furthermore, the introduction of needles that are easier to handle and operate is making EUS-FNB procedures more efficient, which is driving increased adoption in clinical practice.
• Expansion into Emerging Markets: As healthcare systems improve in emerging markets, there is a growing trend toward the adoption of EUS-FNB technology. Countries like India, China, and Brazil are seeing an increase in the use of advanced diagnostic tools as healthcare infrastructure improves. This trend is supported by the rising incidence of cancers, which drives demand for more accurate diagnostic techniques. As affordability and access to EUS-FNB systems improve, these markets represent significant growth opportunities for both global manufacturers and local medical device companies.
These emerging trends—minimally invasive procedures, technological integration with imaging, AI-assisted diagnostics, improved needle designs, and expansion into emerging markets—are reshaping the EUS-FNB market. These developments are improving diagnostic accuracy, reducing patient discomfort, and enhancing the overall quality of healthcare. The combination of these trends is expected to drive further innovation and expansion in the EUS-FNB market.
Recent Development in the EUS-Guided Fine Needle Biopsy Market
Several recent developments are shaping the EUS-guided fine needle biopsy market, improving diagnostic precision and patient care. These developments reflect ongoing advancements in technology, design, and accessibility.
• Advancement of Needle Technologies: Recent advancements in EUS-FNB needles focus on improving the precision and efficiency of tissue collection. New needle designs allow for larger tissue samples with less trauma, reducing the likelihood of complications like bleeding. These advancements are essential in improving the success rates of biopsies, especially in difficult-to-access areas like the pancreas. The availability of needles with better maneuverability and enhanced tissue acquisition capabilities is expected to continue driving market growth.
• AI Integration in Diagnostic Procedures: The integration of artificial intelligence into EUS-FNB procedures is one of the most notable developments. AI technologies are now being used to assist in interpreting ultrasound images, improving the accuracy of needle placement. This ensures that tissue samples are obtained from the most relevant areas, improving diagnostic yields and reducing errors. As AI continues to evolve, it is expected to become an essential tool in the EUS-FNB process, increasing efficiency and enhancing overall outcomes.
• Improved EUS Imaging Technologies: Significant advancements have been made in EUS imaging systems, enhancing the accuracy and ease of performing fine needle biopsies. High-resolution imaging and real-time visualization allow clinicians to better identify target areas, reducing the risk of errors. These improved imaging systems are particularly important for detecting cancers in the early stages, which is crucial for effective treatment. The combination of enhanced imaging and precise needle technology is expected to further strengthen the role of EUS-FNB in diagnostics.
• Global Expansion of EUS-FNB Systems: EUS-FNB systems are expanding globally, with increasing adoption in emerging markets. In regions like India and China, where cancer rates are rising, the demand for accurate diagnostic tools like EUS-FNB is growing rapidly. Additionally, international medical device companies are focusing on making these systems more affordable and accessible to healthcare providers in developing markets. The global expansion of EUS-FNB technology is expected to drive market growth and improve healthcare access in underserved regions.
• Integration of Robotic Assistance: Robotic-assisted EUS systems are another development that is transforming the EUS-FNB market. These systems offer enhanced precision and control during the biopsy procedure, improving the overall accuracy of tissue sampling. Robotic systems also reduce the potential for human error, enabling more consistent outcomes. As robotics become more widely integrated into medical practices, the EUS-FNB market is expected to experience further growth and innovation.
Recent developments such as advancements in needle technologies, AI integration, improved EUS imaging, global expansion, and robotic assistance are reshaping the EUS-FNB market. These innovations are improving diagnostic accuracy, increasing procedure efficiency, and expanding access to this essential diagnostic tool, driving the market’s growth.
Strategic Growth Opportunities in the EUS-Guided Fine Needle Biopsy Market
The EUS-guided fine needle biopsy market offers several strategic growth opportunities driven by advancements in technology, rising demand for early cancer detection, and improvements in healthcare infrastructure.
• Cancer Diagnostics: One of the most significant growth opportunities in the EUS-FNB market is in cancer diagnostics. The rising incidence of cancers, particularly gastrointestinal cancers, is driving the demand for more accurate and less invasive diagnostic tools. EUS-FNB allows for early-stage cancer detection, which is crucial for effective treatment. As awareness of early cancer screening grows, there is an increasing need for advanced biopsy systems, making this an area of high growth potential.
• Minimally Invasive Surgery: With the shift toward minimally invasive surgery, there is increasing adoption of EUS-FNB as a diagnostic tool. Minimally invasive techniques allow for faster recovery, less patient discomfort, and lower complication rates. EUS-FNB procedures are integral to this trend, as they enable clinicians to obtain accurate tissue samples with minimal patient risk. As demand for minimally invasive treatments rises, so too does the adoption of EUS-FNB technology.
• Technological Integration: The integration of AI, robotics, and advanced imaging systems into EUS-FNB procedures presents a significant opportunity for growth. AI can enhance the accuracy of biopsies by assisting with image interpretation, while robotics can improve precision and control during the procedure. These technological advancements offer a competitive edge to manufacturers and healthcare providers, creating opportunities for market expansion and improved patient outcomes.
• Emerging Markets: The expansion of healthcare infrastructure in emerging markets such as India, China, and Latin America presents a valuable growth opportunity for the EUS-FNB market. With rising cancer rates and increased healthcare investments, these regions are expected to see growing demand for advanced diagnostic tools. Companies that can offer affordable and accessible EUS-FNB systems will have significant opportunities to capture market share in these expanding markets.
• Personalized Medicine: Personalized medicine, which tailors treatments to individual patients based on genetic information, is creating new growth opportunities for the EUS-FNB market. EUS-FNB is vital in obtaining tissue samples for genetic testing, allowing clinicians to create customized treatment plans. As personalized medicine becomes more prevalent, the demand for precise and accurate tissue samples will drive the growth of the EUS-FNB market.
The strategic growth opportunities in cancer diagnostics, minimally invasive surgery, technological integration, emerging markets, and personalized medicine are expected to shape the future of the EUS-FNB market. As these trends evolve, the market will continue to expand, offering new avenues for innovation and improved patient care.
EUS-Guided Fine Needle Biopsy Market Driver and Challenges
The EUS-guided fine needle biopsy market is influenced by various drivers and challenges that shape its growth trajectory. These include technological advancements, rising healthcare demand, economic factors, and regulatory hurdles.
The factors responsible for driving the EUS-guided fine needle biopsy market include:
1. Technological Advancements: Innovations in EUS systems and biopsy needles are the primary drivers behind the marketÄX%$%Xs growth. These advancements improve precision, reduce complications, and enhance patient outcomes. The integration of AI and robotics into biopsy procedures further boosts market potential.
2. Rising Cancer Prevalence: The increasing global prevalence of cancers, particularly gastrointestinal cancers, is driving demand for early diagnostic tools. EUS-FNB allows for accurate tissue sampling, enabling early-stage cancer detection and improving treatment outcomes.
3. Minimally Invasive Procedures: The trend toward minimally invasive diagnostic techniques is a key driver of market growth. EUS-FNB offers a less invasive alternative to traditional biopsy methods, making it more appealing to patients and clinicians.
4. Improved Healthcare Infrastructure: The growing focus on healthcare infrastructure development in emerging markets, such as India and China, is driving the adoption of EUS-FNB systems. As access to advanced medical technologies improves, these markets present significant growth opportunities.
5. Personalized Medicine: The shift toward personalized medicine, which relies on precise diagnostic tools, is increasing demand for EUS-FNB procedures. These biopsies provide essential tissue samples for genetic and molecular testing, facilitating tailored treatment plans for patients.
Challenges in the EUS-guided fine needle biopsy market are:
1. High Costs of Equipment: The high cost of advanced EUS-FNB systems can limit their adoption, particularly in price-sensitive markets. Manufacturers are working to reduce costs without compromising on technology and quality.
2. Regulatory Barriers: Stringent regulatory requirements for medical devices can delay market entry and hinder the adoption of new technologies. Compliance with these regulations is essential but can be time-consuming and costly.
3. Lack of Awareness in Emerging Markets: Limited awareness of the benefits of advanced diagnostic techniques in emerging markets can slow the adoption of EUS-FNB. Educational initiatives are needed to increase understanding and adoption of this technology.
The EUS-guided fine needle biopsy market is driven by technological advancements, rising cancer prevalence, and the increasing demand for minimally invasive procedures. However, challenges such as high equipment costs, regulatory barriers, and limited awareness in emerging markets need to be addressed to ensure continued market growth.
List of EUS-Guided Fine Needle Biopsy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies EUS-guided fine needle biopsy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the EUS-guided fine needle biopsy companies profiled in this report include-
• Olympus
• Medtronic
• Cook Medical
• Boston Scientific
• ConMed Corporation
EUS-Guided Fine Needle Biopsy Market by Segment
The study includes a forecast for the global EUS-guided fine needle biopsy market by type, application, and region.
EUS-Guided Fine Needle Biopsy Market by Type [Value from 2019 to 2031]:
• Enteral Endoscopic Ultrasound Needles
• Bronchial Endoscopic Ultrasound Needles
EUS-Guided Fine Needle Biopsy Market by Application [Value from 2019 to 2031]:
• Hospitals
• Clinics
• Others
EUS-Guided Fine Needle Biopsy Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the EUS-Guided Fine Needle Biopsy Market
The EUS-guided fine needle biopsy (EUS-FNB) market has witnessed significant advancements in recent years, driven by technological improvements in endoscopic ultrasound (EUS) procedures and the increasing demand for minimally invasive diagnostic techniques. This market, which provides essential tissue samples for diagnosing a range of conditions such as cancers, has seen notable developments in countries like the United States, China, Germany, India, and Japan. These developments are influenced by factors such as healthcare infrastructure, innovation in medical devices, and increasing awareness of the benefits of EUS-FNB in early-stage disease detection.
• United States: In the United States, the EUS-FNB market is experiencing significant growth due to advancements in endoscopic technologies and the growing adoption of minimally invasive diagnostic procedures. Recent developments include the introduction of needle technologies with improved capabilities for obtaining high-quality tissue samples, even in difficult-to-reach areas. Additionally, the U.S. has seen increased use of EUS-FNB in diagnosing pancreatic cancer, with a growing number of healthcare facilities integrating this technique into routine diagnostic protocols. Reimbursement policies and the widespread adoption of EUS as a diagnostic tool in gastrointestinal procedures further support the market’s expansion.
• China: The Chinese EUS-FNB market is evolving rapidly, with rising cancer rates and a shift toward more sophisticated diagnostic procedures. The country is investing in both the development and adoption of advanced medical technologies, including EUS systems and biopsy needles. This expansion is driven by the increasing demand for early cancer detection and the preference for minimally invasive procedures. Local manufacturers are also improving the affordability and accessibility of EUS-FNB technologies, allowing for broader usage in hospitals and clinics. The Chinese government’s focus on improving healthcare infrastructure is further facilitating the growth of this market.
• Germany: Germany remains one of the leading markets for EUS-FNB in Europe, driven by its advanced healthcare system and emphasis on precision medicine. Recent developments include the introduction of cutting-edge biopsy needles and EUS systems designed for improved tissue acquisition and patient comfort. Additionally, Germany is seeing more collaborative research efforts between medical device companies and healthcare providers to enhance the accuracy and reliability of EUS-FNB procedures. The countryÄX%$%Xs strong healthcare infrastructure, coupled with increasing awareness of the benefits of early cancer detection, supports the steady growth of the EUS-FNB market.
• India: The Indian EUS-FNB market is gaining momentum, particularly in major cities where healthcare infrastructure is rapidly advancing. With the increasing prevalence of cancers, especially gastrointestinal cancers, there is a growing need for precise diagnostic tools like EUS-FNB. Recent advancements include the introduction of more affordable EUS systems and biopsy needles, which have made the technology more accessible to Indian hospitals and clinics. The shift toward non-invasive procedures is also contributing to the rising demand for EUS-FNB, helping clinicians accurately diagnose conditions with fewer complications and quicker recovery times.
• Japan: JapanÄX%$%Xs healthcare system continues to embrace the latest innovations in EUS-FNB, with a focus on improving diagnostic accuracy and patient outcomes. Japan is known for its early adoption of advanced medical technologies, and recent developments in the EUS-FNB market include enhanced biopsy needles and the integration of AI-assisted imaging to aid in more accurate tissue sampling. The aging population and increasing incidence of gastrointestinal cancers are key drivers of EUS-FNB adoption in the country. Additionally, JapanÄX%$%Xs strong emphasis on research and development supports the continuous innovation in EUS technology, helping clinicians achieve more precise diagnoses.
Features of the Global EUS-Guided Fine Needle Biopsy Market
Market Size Estimates: EUS-guided fine needle biopsy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: EUS-guided fine needle biopsy market size by type, application, and region in terms of value ($B).
Regional Analysis: EUS-guided fine needle biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the EUS-guided fine needle biopsy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the EUS-guided fine needle biopsy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for EUS-guided fine needle biopsy market?
Answer: The global EUS-guided fine needle biopsy market is expected to grow with a CAGR of 5.5% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the EUS-guided fine needle biopsy market?
Answer: The major drivers for this market are the rising accuracy and diagnostic capabilities and the growing adoption of minimally invasive procedures.
Q3. What are the major segments for EUS-guided fine needle biopsy market?
Answer: The future of the EUS-guided fine needle biopsy market looks promising with opportunities in the hospitals and clinics markets.
Q4. Who are the key EUS-guided fine needle biopsy market companies?
Answer: Some of the key EUS-guided fine needle biopsy companies are as follows:
• Olympus
• Medtronic
• Cook Medical
• Boston Scientific
• ConMed Corporation
Q5. Which EUS-guided fine needle biopsy market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, enteral endoscopic ultrasound needles are expected to witness higher growth over the forecast period.
Q6. In EUS-guided fine needle biopsy market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the EUS-guided fine needle biopsy market by type (enteral endoscopic ultrasound needles and bronchial endoscopic ultrasound needles), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to EUS-Guided Fine Needle Biopsy Market, EUS-Guided Fine Needle Biopsy Market Size, EUS-Guided Fine Needle Biopsy Market Growth, EUS-Guided Fine Needle Biopsy Market Analysis, EUS-Guided Fine Needle Biopsy Market Report, EUS-Guided Fine Needle Biopsy Market Share, EUS-Guided Fine Needle Biopsy Market Trends, EUS-Guided Fine Needle Biopsy Market Forecast, EUS-Guided Fine Needle Biopsy Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.